ArticleHepatology (Baltimore, Md.)2013
The antimalarial ferroquine is an inhibitor of hepatitis C virus.
Article in Hepatology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Drug repurposing: a promising drug discovery strategy for the treatment of emerging epidemic infectious disease.Molecular diversity · 2026Review
- Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.Pharmaceutics · 2022Review
- Entry Inhibitors of Hepatitis C Virus.Advances in experimental medicine and biology · 2022Article
- 4-Aminoquinoline compounds from the Spanish flu to COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- COVID-19 Diagnostics, Tools, and Prevention.Diagnostics (Basel, Switzerland) · 2020Review
- Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.Journal of virology · 2017Article
- A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.Scientific reports · 2017Article
- Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.Pharmacology research & perspectives · 2017Review
- Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.Journal of virology · 2016Article
- Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Hepatology international · 2016Review
- Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model.World journal of hepatology · 2016Article
- Entry inhibitors: New advances in HCV treatment.Emerging microbes & infections · 2016Review
- Review
- New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.Journal of virology · 2015Article
- Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Science translational medicine · 2015Article
- Chloroquine-containing compounds: a patent review (2010 - 2014).Expert opinion on therapeutic patents · 2015Review
- Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity.Antiviral research · 2014Article
- How hepatitis C virus invades hepatocytes: the mystery of viral entry.World journal of gastroenterology · 2014Review
- Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.PloS one · 2014Article
- Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledHepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti-HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)-free treatments. Here, we report that ferroquine (FQ), an antimalarial ferrocenic analog of chloroquine, is a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines by affecting an early step of the viral life cycle. The antiviral activity of FQ on HCV entry was confirmed with pseudoparticles expressing HCV envelope glycoproteins E1 and E2 from six different genotypes. In addition to its effect on HCV entry, FQ also inhibited HCV RNA replication, albeit at a higher concentration. We also showed that FQ has no effect on viral assembly and virion secretion. Using a binding assay at 4°C, we showed that FQ does not prevent attachment of the virus to the cell surface. Furthermore, virus internalization was not affected by FQ, whereas the fusion process was impaired in the presence of FQ as shown in a cell-cell fusion assay. Finally, virus with resistance to FQ was selected by sequential passage in the presence of the drug, and resistance was shown to be conferred by a single mutation in E1 glycoprotein (S327A). By inhibiting cell-free virus transmission using a neutralizing antibody, we also showed that FQ inhibits HCV cell-to-cell spread between neighboring cells. Combinations of FQ with IFN, or an inhibitor of HCV NS3/4A protease, also resulted in additive to synergistic activity.
conclusionFQ is a novel, interesting anti-HCV molecule that could be used in combination with other direct-acting antivirals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.